Menu

Prominent Mouse Genetics Center Could be Shuttered

Staff at the UK’s Harwell Institute were notified that a strategy board recommended halting its academic work, but a final decision is months away.

Jun 21, 2019
Shawna Williams

ABOVE: © ISTOCK.COM, DRA_SCHWARTZ

Britain’s Medical Research Council has notified staff at its Harwell Institute, located near Oxford, that academic work there may end, following the recommendation of an internal strategy board, The Guardian reported yesterday (June 20). The change would mean the closure of the institute’s Mouse Genetics Unit (MGU), which employs 125 researchers and 40 support staff, according to the newspaper.

“We’re perplexed,” MGU director Steve Brown tells The Guardian. “We don’t understand the decision. We need to have a pause to consider the impact on British science.” 

According to its website, the Harwell Institute’s research areas include neurodegeneration, deafness, and diabetes. The institute’s Mary Lyon Centre, which provides mouse services to researchers, would not be affected by the proposed closure.

Noting the recent closure of another UK animal facility, that one run by Wellcome Sanger, Brown says in comments to The Guardian that to close both would be a “double whammy” for mouse research. “We have to be extremely careful that we do not undermine what is a critical area of biomedical science,” he says. “This is a major threat to UK science and a weakening of our position at the forefront of genomic and precision medicine.”

See “Wellcome Sanger Institute to Close Animal Facility

In its email to Harwell staff, the Medical Research Council (MRC) said that the proposed closure “is no reflection upon the value or quality of MGU science, but a reflection of the changing scientific landscape. Detailed proposals are now being developed in line with these recommendations, in consultation with staff. A final decision on the way forward will be made by MRC council in December 2019. MRC is supporting its dedicated staff during this challenging time,” The Guardian reports.

Robin Lovell-Badge, a geneticist at the Francis Crick Institute in London, tells the publication: “I am dismayed at this decision. The mouse genetics research that has been carried out at Harwell had been world-leading.” 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.